Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.75 USD

38.75
1,269,966

-0.41 (-1.05%)

Updated Jul 15, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GlaxoSmithKline (GSK) Stock Moves -0.33%: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $45.69, marking a -0.33% move from the previous day.

Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA

by Zacks Equity Research

Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $45.89, marking a -0.67% move from the previous day.

Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months

by Zacks Equity Research

Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.

Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More

by Zacks Equity Research

Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

by Zacks Equity Research

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

by Zacks Equity Research

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $46.85, moving +0.69% from the previous trading session.

Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug

by Zacks Equity Research

The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.

Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed

by Zacks Equity Research

Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.

Ekta Bagri headshot

Antibody Treatments for COVD-19 Face Challenges in the U.S.

by Ekta Bagri

With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.

GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $46.23, marking a +1.12% move from the previous day.

VIR Stock Down on Another Setback for COVID-19 Antibody

by Zacks Equity Research

VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS

by Kinjel Shah

FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.

GlaxoSmithKline (GSK) Stock Moves -0.32%: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $43.56, moving -0.32% from the previous trading session.

Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

by Zacks Equity Research

The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.

VIR Stock Gains on News of Inclusion in the S&P SmallCap 600

by Zacks Equity Research

Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.

J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents

by Zacks Equity Research

The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.

AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.

FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy

by Zacks Equity Research

The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $43.28 in the latest trading session, marking a -0.05% move from the prior day.

Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.

Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma

by Zacks Equity Research

Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.

GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $43.30, moving +0.91% from the previous trading session.